Myocardial Perfusion Imaging
3
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
ASPRUZYO SPRINKLEApproved
ranolazine
Unknown CompanyAnti-anginal [EPC]oral2022
Competitive Landscape
3 companies ranked by most advanced pipeline stage
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Lantheus Medical ImagingDefinity
Gilead SciencesRanolazine
GuerbetGadavist 15Ml Solution for Injection
Clinical Trials (3)
Total enrollment: 171 patients across 3 trials
Real-Time Myocardial Perfusion Echocardiography in the ICU
Start: Sep 2017Est. completion: Dec 2019
Phase 4Completed
Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
Start: Sep 2010Est. completion: Sep 201281 patients
Phase 4Completed
Dotarem Evaluation for Myocardial Perfusion CMR
Start: Jul 2019Est. completion: Oct 202490 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space